Events

ATTENTION: Due to the COVID-19 PANDEMIC, many events are being rescheduled for a later date, converted into virtual venues, or altogether cancelled. Please check with the event organizer or website prior to planning for any forthcoming event.

Fast, Accurate and Portable Molecular Analyzer to Revolutionize Diagnostics

By LabMedica International staff writers
Posted on 03 Sep 2022

Image: Genomadix Cube is a fast, accurate, and portable molecular analyzer that uses the same PCR technology as a full service lab (Photo courtesy of Genomadix)

The increase in the prevalence of infectious diseases and the onset of the COVID-19 pandemic has led to an increase in lab testing in order to keep pace with rising cases across the world. However, traditional lab-based tests can take days to weeks for results. Now, a fast, accurate, and portable DNA analyzer goes from sample to result in approximately an hour and delivers quality results outside of a lab.

Genomadix Inc.’s (Kanata, ON, Canada) Genomadix Cube is a portable, molecular analyzer that uses polymerase chain reaction (PCR) technology to generate relatively quick, accurate test results, outside of a healthcare facility. Designed to be used as a decentralized testing option, the analyzer is especially helpful for remote communities and remote industries where access to a full lab may be difficult. Samples are collected and inserted into a single-use DNA test cartridge. Inside the analyzer, the cartridge extracts the DNA/RNA and makes millions of copies based on PCR. An optical system detects the increased fluorescence and algorithms automatically generate a test result.

The Genomadix Cube automates complex and tedious manual procedures, advancing sample to result DNA/RNA testing in clinical, environmental, infectious disease, and precision medicine. The testing system already delivers environmental testing for potentially deadly Legionella bacteria in water sources such as building cooling towers and CYP2C19 genotype guided antiplatelet therapy in Europe with efforts underway for US authorization. Additionally, a COVID-19 product has been developed with introduction slated (pending authorization) for later in 2022. These tests are run using their own unique software on the Genomadix Cube.

Related Links:
Genomadix Inc.